Metronomic chemotherapy (mCHT) in HER2-ve advanced breast cancer (ABC) patients (pts): Final results of the VICTOR-6 study.

e13076Background: mCHT is the minimum biologically effective dose of a CHT agent, given at regular dosing regimen with no prolonged drug free interval. Aim of this observational retrospective study is to describe the use of mCHT in ABC pts across 5 years and efficacy of old (CM-like) vs new (VRL/CAPE-based) metronomic regimens in terms of response and disease control. Methods: We retrospectively identified from clinical records those HER2-ve ABC pts who have received any kind of mCHT in the years 2011-2015, alone, or in combination with a non-metronomic drug. Standard statistical approaches were used for describing the sample characteristics. This analysis focuses on Response Rate (RR) and Disease Control Rate (DCR). Results: From June 2011 to December 2015, 601 pts have been enrolled. Main tumour characteristics were ductal histology (84.2%), pT2 stage (41.6%), pN1 stage (35.2%), ER+/PgR+ (81%), Grade 2 (47.1%). ECOG PS was 0-1 in most patients (92.0%). mCHT use increased over the time from 15.0% (2011) ...